Improvements in urticaria control and quality of life among patients with chronic inducible urticaria were observed with 20 weeks of barzolvolimab.

Clinical data show remibrutinib treatment leads to significant reductions in urticaria activity scores compared with placebo within the first week.

Patients with chronic spontaneous urticaria had positive outcomes weeks after barzolvolimab, according to data presented at ...

Regeneron and Sanofi win CHMP backing to expand Dupixent use to young CSU patients, with EU and U.S. decisions poised to unlock a new growth avenue.

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms ...

Hives, or urticaria, are a common skin rash that appears as raised, itchy welts. Sometimes, hives resolve quickly on their own, but if they persist, over-the-counter medications often help. Hives ...

With barzolvolimab re-treatment, 62% of patients with ColdU and 60% of patients with SD had a complete response at Week 20 in the OLE. These findings are consistent with the complete response rates in ...

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with ...

If you’ve developed a rash that’s hot, swollen, bumpy, or itchy, it’s possible you have hives. Finding hives on your skin can be unsettling, and usually you can’t be sure where they came from. No ...

September 29, 2006 —The US Food and Drug Administration (FDA) has approved first-time generic formulations for caffeine citrate 10-mg/mL intravenous injection and 10-mg/mL oral solution for the ...

Medically reviewed by Katlein Franca, MD Doctors use a process of elimination to diagnose chronic hives, rather than a single ...

Add Yahoo as a preferred source to see more of our stories on Google. If you notice red, itchy welts suddenly popping up on your skin, you may start to panic. Are you having an allergic reaction? Did ...